Get the Stockscreener App
56.70
0.91%
0.51
After Hours:
56.79
0.09
+0.16%
Twist Bioscience Corp stock is traded at $56.70, with a volume of 1.64M.
It is up +0.91% in the last 24 hours and up +12.93% over the past month.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
See More
Previous Close:
$56.19
Open:
$58.32
24h Volume:
1.64M
Relative Volume:
1.21
Market Cap:
$3.48B
Revenue:
$391.56M
Net Income/Loss:
$-76.58M
P/E Ratio:
-44.49
EPS:
-1.2745
Net Cash Flow:
$-86.72M
1W Performance:
-4.14%
1M Performance:
+12.93%
6M Performance:
+79.89%
1Y Performance:
+57.81%
1-Day Range:
$55.67
$60.44
1-Week Range:
$55.67
$60.95
52-Week Range:
$23.30
$66.06
Twist Bioscience Corp Stock (TWST) Company Profile
Name
Twist Bioscience Corp
Sector
Industry
Phone
800-719-0671
Address
681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA
Compare TWST vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TWST
Twist Bioscience Corp
|
56.70 | 3.45B | 391.56M | -76.58M | -86.72M | -1.2745 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Twist Bioscience Corp Stock (TWST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Initiated | Stephens | Overweight |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Jun-04-24 | Initiated | Guggenheim | Buy |
| Jan-17-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-27-23 | Initiated | Berenberg | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-29-21 | Initiated | William Blair | Outperform |
| Jun-04-21 | Initiated | Goldman | Neutral |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Feb-05-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-04-21 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-20 | Initiated | SVB Leerink | Mkt Perform |
| May-31-19 | Initiated | Evercore ISI | Outperform |
| Nov-26-18 | Initiated | JP Morgan | Neutral |
View All
Twist Bioscience Corp Stock (TWST) Latest News
These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results - Benzinga
Twist Bioscience Corporation (NASDAQ:TWST) Q2 2026 Earnings Call Transcript - Insider Monkey
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Twist Bioscience Q2 2026 Financials: Forward-Looking Statements, Risks, and Results from Nasdaq Global Select – Form 10-Q - Minichart
MSN Money - MSN
Twist Bioscience Reports 19% Revenue Growth, Stock Ticker TWST - GuruFocus
Twist Bioscience (TWST) Reports 19.3% Revenue Growth in Q2 Fisca - GuruFocus
Revenue climbs at Twist Bioscience (NASDAQ: TWST) as losses and cash burn persist - Stock Titan
TWST (NASDAQ: TWST) Emily Leproust files Rule 144 listing multiple share sales - Stock Titan
Affiliate sale notice at TWST (NASDAQ: TWST) lists 1,116 restricted shares - Stock Titan
Proposed resale of 2,844 shares by reporting person (TWST) - Stock Titan
[144] Twist Bioscience Corp SEC Filing - Stock Titan
TWST (NASDAQ: TWST) Rule 144 notice after restricted stock vesting - Stock Titan
AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens - Benzinga
TD Cowen raises Twist Bioscience stock price target on revenue beat - Investing.com
Twist Bioscience (TWST) Unveils Expanded Clonal Genes Portfolio - GuruFocus
Twist Bioscience Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
TWST Forecasts Growth Driven by NGS - GuruFocus
Twist Bioscience Achieves Record Q2 2026 Revenue, Raises Full-Year Guidance and Targets Adjusted EBITDA Breakeven in Q4 - Minichart
Twist Bioscience (TWST) Aims for Adjusted EBITDA Breakeven in Q4 - GuruFocus
Twist Bioscience Q2 FY2026 slides: revenue beats guidance, margins expand - Investing.com
Twist Bioscience Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Twist Bioscience Q2 2026 EPS miss, stock rises - Investing.com
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Twist Bioscience misses earnings despite revenue beat By Investing.com - Investing.com South Africa
Twist Bioscience misses earnings despite revenue beat - Investing.com
TWIST BIOSCIENCE ($TWST) Releases Q2 2026 Earnings - Quiver Quantitative
Twist Bioscience launches complex gene synthesis service By Investing.com - Investing.com South Africa
Twist Bioscience launches complex gene synthesis service - Investing.com
Twist Bioscience: Fiscal Q2 Earnings Snapshot - wwltv.com
Twist Bioscience (NASDAQ: TWST) lifts FY26 outlook after 19% Q2 growth - Stock Titan
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences - Business Wire
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results - Business Wire
Pictet Asset Management Holding SA Grows Holdings in Twist Bioscience Corporation $TWST - MarketBeat
Twist Bioscience Investors Seek $17M Stock Fraud Deal OK - Law360
TWSTTwist Bioscience Corp Stock Price and Quote - Finviz
Twist Bioscience faces earnings test as breakeven path looms - Investing.com UK
Twist Bioscience faces earnings test as breakeven path looms By Investing.com - Investing.com UK
Vanguard reports 3.10M-share (5.05%) stake in Twist Bioscience (NASDAQ: TWST) - Stock Titan
ARK Investment Management reports 10.35% stake in Twist Bioscience (NASDAQ: TWST) - Stock Titan
Insider Sell: Melissa Starovasnik Sells 500 Shares of Twist Bios - GuruFocus
Melissa Starovasnik Sells 500 Shares of Twist Bioscience (NASDAQ:TWST) Stock - MarketBeat
Director at Twist Bioscience (NASDAQ: TWST) sells 500 shares - Stock Titan
Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
TWST News | TWIST BIOSCIENCE CORP (NASDAQ:TWST) - ChartMill
Twist Bioscience president and COO Finn sells $141,026 in stock By Investing.com - Investing.com South Africa
Twist Bioscience president and COO Finn sells $141,026 in stock - Investing.com
Tax-cover sale by Twist Bioscience (NASDAQ: TWST) president - Stock Titan
500-share sale listed; TWST (NASDAQ: TWST) Form 144 notice - Stock Titan
Twist Bioscience (TWST) to Release Earnings on Monday - MarketBeat
TWST Price Today: Twist Bioscience Corporation Stock Price, Quote & Chart | MEXC - MEXC Exchange
Twist Bioscience Corp Stock (TWST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):